Skip to main content

Market Overview

Jefferies Reiterates Buy on Amarin Corporation on Continued Positive Outlook

Share:

In a report published Thursday, Jefferies analyst Thomas Wei reiterated a Buy rating and $20.00 price target on Amarin Corporation plc (NASDAQ: AMRN).

In the report, Jefferies noted, “We outline several reasons why we remain positive on near term approval prospects for the Vascepa ANCHOR indication in advance of the advisory committee meeting set for October 16 and the expected release of the FDA's briefing documents on Friday (October 11). The ANCHOR Indication of mixed dyslipidemia is critical for long-term Vascepa sales growth and we view it as central to our AMRN Buy thesis.”

Amarin Corporation plc closed on Wednesday at $6.30.

Latest Ratings for AMRN

DateFirmActionFromTo
Feb 2021SVB LeerinkMaintainsOutperform
Sep 2020SVB LeerinkMaintainsOutperform
Aug 2020Piper SandlerInitiates Coverage OnOverweight

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

 

Related Articles (AMRN)

View Comments and Join the Discussion!

Posted-In: Jefferies Thomas WeiAnalyst Color Reiteration Analyst Ratings

Latest Ratings

StockFirmActionPT
CWells FargoMaintains82.0
MRTXOppenheimerMaintains255.0
KRTXOppenheimerMaintains148.0
MNSTArgus ResearchMaintains100.0
STRABarrington ResearchMaintains120.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com